#1 Clinical Trials Search in Europe

Pevonedistat

Pevonedistat is an investigational drug being studied in clinical trials for the treatment of various blood cancers and solid tumors. These trials are exploring pevonedistat alone and in combination with other cancer drugs to determine its safety, effectiveness, and optimal dosing. The studies focus on conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and advanced solid tumors in patients who may not be eligible for standard treatments.

Table of Contents

What is Pevonedistat?

Pevonedistat is an investigational drug being studied for the treatment of various blood cancers and solid tumors. It is also known by other names such as MLN4924, TAK-924, and Nedd8-Activating Enzyme Inhibitor MLN4924[1][2]. This medication is currently being tested in clinical trials to determine its safety and effectiveness in treating different types of cancer.

How Does Pevonedistat Work?

Pevonedistat works by blocking certain enzymes that cancer cells need to grow and divide. Specifically, it inhibits an enzyme called NEDD8-activating enzyme (NAE)[3]. By interfering with this enzyme, pevonedistat may help stop the growth of cancer cells or even cause them to die. This unique mechanism of action makes pevonedistat a promising candidate for cancer treatment, especially when combined with other cancer therapies.

What Conditions Does Pevonedistat Treat?

Pevonedistat is being studied for the treatment of several types of cancer, including:

  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow and blood[1][3]
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[1][3]
  • Chronic Myelomonocytic Leukemia (CMML): A type of blood cancer that affects certain white blood cells[1]
  • Advanced Solid Tumors: Various types of cancers that form solid masses in the body[2]

Pevonedistat is being investigated for both newly diagnosed patients and those whose cancer has come back (relapsed) or hasn’t responded to other treatments (refractory)[4].

How is Pevonedistat Administered?

Pevonedistat is typically given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The dosage and schedule can vary depending on the specific study and the patient’s condition. In many trials, pevonedistat is administered on specific days within a treatment cycle, often on days 1, 3, and 5 of a 21-day or 28-day cycle[1][3].

Pevonedistat in Combination Therapy

Researchers are studying pevonedistat both as a single agent and in combination with other cancer treatments. Some common combinations include:

  • Pevonedistat + Azacitidine: This combination is being studied for AML and MDS. Azacitidine is a chemotherapy drug that can help bone marrow produce normal blood cells and kill abnormal cells[1][5]
  • Pevonedistat + Docetaxel: This combination is being tested in solid tumors. Docetaxel is a chemotherapy drug that interferes with cell division[6]
  • Pevonedistat + Paclitaxel + Carboplatin: This triple combination is also being studied for solid tumors. Paclitaxel and carboplatin are chemotherapy drugs that work in different ways to stop cancer cell growth[6]
  • Pevonedistat + Pembrolizumab: This combination is being investigated for certain types of solid tumors. Pembrolizumab is an immunotherapy drug that helps the immune system fight cancer cells[7]

Potential Side Effects

As with any medication, pevonedistat may cause side effects. The full range of potential side effects is still being studied in clinical trials. Researchers are carefully monitoring patients for any adverse reactions. Common side effects observed in cancer treatments may include fatigue, nausea, decreased blood cell counts, and increased risk of infections. It’s important to note that the side effect profile may vary when pevonedistat is combined with other treatments[1][2].

Ongoing Research

Several clinical trials are currently underway to further investigate the effectiveness and safety of pevonedistat. These studies are looking at various aspects, including:

  • The best dose of pevonedistat when used alone or in combination with other drugs[3]
  • How pevonedistat affects patients with kidney or liver problems[1]
  • The effectiveness of pevonedistat compared to standard treatments[5]
  • How pevonedistat might help patients whose cancer has returned or hasn’t responded to other treatments[4]
  • The potential of pevonedistat in treating patients with minimal residual disease (small numbers of cancer cells that remain after treatment)[8]

These ongoing studies will help researchers better understand how pevonedistat works, who it might help the most, and how to use it safely and effectively in cancer treatment.

Aspect Details
Drug Name Pevonedistat (also known as MLN4924)
Cancer Types Studied Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Advanced Solid Tumors
Common Combination Therapies Azacitidine, Low-dose Cytarabine, Docetaxel, Carboplatin, Paclitaxel
Administration Method Intravenous infusion, typically on days 1, 3, and 5 of treatment cycles
Key Outcomes Measured Overall survival, Event-free survival, Response rates, Safety and tolerability
Patient Populations Newly diagnosed, relapsed/refractory, older/unfit for standard chemotherapy
Biomarkers Explored NPM1, FLT3-ITD, CBF, P53, IDH1/IDH2 mutations

FAQ

  • What is pevonedistat and how does it work? Pevonedistat is an investigational drug that works by blocking enzymes needed for cancer cell growth. It inhibits a protein called NEDD8-activating enzyme, which may help stop tumor cells from dividing and spreading.
  • What types of cancer is pevonedistat being studied for? Pevonedistat is being studied for blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as advanced solid tumors. It's being tested in patients who may not be eligible for standard chemotherapy treatments.
  • How is pevonedistat given to patients in clinical trials? In most trials, pevonedistat is given as an intravenous (IV) infusion, typically on days 1, 3, and 5 of each treatment cycle. It is often combined with other cancer drugs like azacitidine or low-dose cytarabine.
  • What are some of the potential side effects being monitored? Researchers are closely monitoring for side effects and adverse events. Common things being tracked include blood count changes, infections, fatigue, nausea, and other symptoms. The trials aim to determine the safest and most effective doses.
  • How can I find out if I'm eligible for a pevonedistat clinical trial? Eligibility criteria vary for each trial, but generally include factors like cancer type, prior treatments, age, and overall health status. You can ask your oncologist about pevonedistat trials or search clinical trial databases for studies that may be appropriate for your situation.

Ongoing Clinical Trials on Pevonedistat

  • Study Comparing Pevonedistat, Venetoclax, and Azacitidine with Venetoclax and Azacitidine in Adults with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy Poland

Glossary

  • Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow and quickly moves into the blood. It affects the production of normal blood cells.
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow does not produce enough healthy blood cells. It can sometimes progress to acute myeloid leukemia.
  • Intravenous (IV): A method of giving medications directly into a vein using a needle or tube.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor or in the extent of cancer in the body in response to treatment.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.

References

  1. https://clinicaltrials.gov/study/NCT03814005
  2. https://clinicaltrials.gov/study/NCT03057366
  3. https://clinicaltrials.gov/study/NCT03459859
  4. https://clinicaltrials.gov/study/NCT03745352
  5. https://clinicaltrials.gov/study/NCT04090736
  6. https://clinicaltrials.gov/study/NCT01862328
  7. https://clinicaltrials.gov/study/NCT04800627
  8. https://clinicaltrials.gov/study/NCT04712942